Diversity in Renal Function Monitoring and Dose Modifications During Treatment for Childhood Cancer: A Call for Standardization

被引：5
作者：
Blufpand, Hester N. [1 ]
Hes, Nicole [1 ]
Bokenkamp, Arend [1 ]
van de Wetering, Marianne D. [2 ]
Kaspers, Gertjan J. L. [1 ]
机构：
[1] Vrije Univ Amsterdam, Med Ctr, NL-1081 HV Amsterdam, Netherlands
[2] Emma Childrens Hosp, Acad Med Ctr, Amsterdam, Netherlands
来源：
PEDIATRIC BLOOD & CANCER | 2014年 / 61卷 / 02期
关键词：
adverse effects; chemotherapy induced nephrotoxicity; childhood cancer; dose modifications in case of renal dysfunction; renal function; IFOSFAMIDE-INDUCED NEPHROTOXICITY; GLOMERULAR-FILTRATION-RATE; CYSTATIN-C; SERUM CREATININE; SARCOMA PATIENTS; KIDNEY-FUNCTION; RISK-FACTORS; CHILDREN; SURVIVORS; CARBOPLATIN;
D O I：
10.1002/pbc.24572
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Despite changes in survival and drug tolerability, nephrotoxicity remains an important complication of chemotherapy. To provide cutting-edge care for children with cancer oncologist must be familiar with their nephrotoxic potential. Careful monitoring of renal function during treatment is therefore indicated. Well-defined guidelines for this are lacking. We reviewed current DCOG protocols and showed that monitoring of renal function during treatment varies widely between protocols. In some protocols recommended renal function measures are inappropriate given the chemotherapy prescribed. Advices on dose modifications in case of renal dysfunction also vary, even with comparable regimens. These differences are unwanted and call for standardization. Pediatr Blood Cancer 2014;61:337-344. (c) 2013 Wiley Periodicals, Inc.
引用
收藏
页码：337 / 344
页数：8
相关论文
共 44 条
  • [1] Comparison of Two Methods for Carboplatin Dosing in Children With Retinoblastoma[J]. Allen, Steven;Wilson, Matthew W.;Watkins, Amy;Billups, Catherine;Qaddoumi, Ibrahim;Haik, Barrett H.;Rodriguez-Galindo, Carlos. PEDIATRIC BLOOD & CANCER, 2010(01)
  • [2] Late Morbidity After Successful Treatment of Children with Cancer[J]. Bhatia, Smita;Constine, Louis S. CANCER JOURNAL, 2009(03)
  • [3] Cystatin C More Accurately Detects Mildly Impaired Renal Function Than Creatinine in Children Receiving Treatment for Malignancy[J]. Blufpand, Hester N.;Tromp, Jorien;Abbink, Floor C. H.;Stoffel-Wagner, Birgit;Bouman, Anneke A.;Schouten-van Meeteren, Antoinette Y. N.;van Wijk, Joanna A. E.;Kaspers, Gertjan J. L.;Bokenkamp, Arend. PEDIATRIC BLOOD & CANCER, 2011(02)
  • [4] STUDIES ON THE ANTI-DIURETIC EFFECT OF CYCLOPHOSPHAMIDE - VASOPRESSIN RELEASE AND SODIUM-EXCRETION[J]. BODE, U;SEIF, SM;LEVINE, AS. MEDICAL AND PEDIATRIC ONCOLOGY, 1980(03)
  • [5] Effect of corticosteroid therapy on low-molecular-weight protein markers of kidney function[J]. Boekenkamp, Arend;Laarman, Celeste A. R. C.;Braam, Katja I.;van Wijk, Joanna A. E.;Kors, Wijnanda A.;Kool, Marijke;de Valk, Janneke;Bouman, Anna A.;Spreeuwenberg, Marieke D.;Stoffel-Wagner, Birgit. CLINICAL CHEMISTRY, 2007(12)
  • [6] Cystatin C - A new marker of glomerular filtration rate in children independent of age and height[J]. Bokenkamp, A;Domanetzki, M;Zinck, R;Schumann, G;Byrd, D;Brodehl, J. PEDIATRICS, 1998(05)
  • [7] Reference values for cystatin C serum concentrations in children[J]. Bökenkamp, A;Domanetzki, M;Zinck, R;Schumann, G;Brodehl, J. PEDIATRIC NEPHROLOGY, 1998(02)
  • [8] IFOSFAMIDE - PHARMACOLOGY, SAFETY AND THERAPEUTIC POTENTIAL[J]. BRADE, WP;HERDRICH, K;VARINI, M. CANCER TREATMENT REVIEWS, 1985(01)
  • [9] PARTIAL REVERSIBILITY OF CISPLATIN NEPHROTOXICITY IN CHILDREN[J]. BROCK, PR;KOLIOUSKAS, DE;BARRATT, TM;YEOMANS, E;PRITCHARD, J. JOURNAL OF PEDIATRICS, 1991(04)
  • [10] Long-term cause-specific mortality among five-year survivors of childhood cancer[J]. Cardous-Ubbink, MC;Heinen, RC;Langeveld, NE;Bakker, PJM;Voûte, PA;Caron, HN;van Leeuwen, FE. PEDIATRIC BLOOD & CANCER, 2004(07)
12345